Deepika Kaveri
About Deepika Kaveri
Deepika Kaveri is an Associate Scientist at Rapt in South San Francisco, California, with a background in T-cell research and genetics. She has held positions at Université De Strasbourg and The Hospital For Sick Children, focusing on T-cell characterization and suppression assays.
Current Role at Rapt Therapeutics
Deepika Kaveri has been serving as an Associate Scientist at Rapt Therapeutics since 2017. In this role, she is involved in various research initiatives aimed at understanding and developing therapeutic strategies. Her work focuses on tumor-intrinsic and extrinsic studies for target engagement, contributing to the advancement of cancer treatment methodologies. Based in South San Francisco, California, she has been part of the team for over seven years.
Previous Experience at The Hospital For Sick Children
Prior to her current position, Deepika Kaveri worked as a Postdoctoral Research Fellow at The Hospital For Sick Children from 2013 to 2015. During her two years there, she specialized in T-cell characterization using phospho-flow techniques. This experience enhanced her expertise in immunology and T-cell biology, further informing her subsequent research endeavors.
Education and Expertise in Genetics
Deepika Kaveri completed her Bachelor's degree in Genetics at Pg Center, Kolar from 2001 to 2004. She further pursued her Master's degree in the same field at the same institution from 2004 to 2006. Deepika then obtained her Doctorate in Philosophy from the University of Strasbourg, where she focused on Notch-independent T-cell leukemia from 2008 to 2012. Her educational background provides a strong foundation for her research in T-cell biology and immunology.
Research Specializations
Deepika Kaveri specializes in the isolation of mouse T-cell subsets and the establishment of T-cell based suppression assays. Her research includes conducting in vitro and in vivo analyses of Treg suppression utilizing flow cytometry and quantitative PCR (qPCR). This specialization contributes to her understanding of immune responses and the development of targeted therapies.